Get the Stockscreener App
18.50
12.05%
1.99
After Hours:
18.41
-0.09
-0.49%
Mbx Biosciences Inc stock is traded at $18.50, with a volume of 126.81K.
It is up +12.05% in the last 24 hours and down -22.82% over the past month.
MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
See More
Previous Close:
$16.51
Open:
$16.75
24h Volume:
126.81K
Relative Volume:
1.38
Market Cap:
$593.66M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+5.05%
1M Performance:
-22.82%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$16.75
$19.00
1-Week Range:
$15.31
$19.16
52-Week Range:
$15.31
$27.50
Mbx Biosciences Inc Stock (MBX) Company Profile
Name
Mbx Biosciences Inc
Sector
Industry
Phone
(317) 989-3100
Address
12406 HORESHAM STREET, CARMEL
Compare MBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| MBX | 18.50 | 593.66M | 0 | 0 | 0 | 0.00 |
| VRTX | 450.97 | 116.38B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 82.09B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.14B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.25B | 3.30B | -501.07M | 1.03B | 11.54 |
Mbx Biosciences Inc Stock (MBX) Latest News
MBX Biosciences (NYSE:MBX) Shares Gap DownHere's What Happened - MarketBeat
MBX Biosciences completes phase 1 trial of diabetes drug - Investing.com India
MBX Biosciences (NYSE:MBX) Shares Gap UpWhat's Next? - MarketBeat
MBX Biosciences Announces Last Subject Last Visit in Phase - GlobeNewswire
Mbx Biosciences, Inc. Announces Last Subject Last Visit in Phase 1 Trial of Mbx 1416 for the Treatment of Post-Bariatric Hypoglycemia - Marketscreener.com
MBX Biosciences (NYSE:MBX) Reaches New 12-Month Low – Here’s Why - Defense World
MBX Biosciences (NYSE:MBX) Sets New 1-Year LowWhat's Next? - MarketBeat
MBX Biosciences: Decent Potential For Lead Indication, But Need More Data (NASDAQ:MBX) - Seeking Alpha
Behind the Bell: MBX Biosciences - Nasdaq
MBX Biosciences Reports Q3 2024 Financial Progress - MSN
Wellington Management Group LLP Acquires New Stake in MBX Biosci - GuruFocus.com
MBX Biosciences Inc. (MBX) Quarterly 10-Q Report - Quartzy
MBX Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
MBX Biosciences Secures $251M in IPO, Advances Clinical Pipeline with Strong Cash Position | MBX Stock News - StockTitan
MBX Biosciences (NYSE:MBX) Shares Up 8.2%Time to Buy? - MarketBeat
MBX Biosciences (NYSE:MBX) Shares Up 6.8%Should You Buy? - MarketBeat
MBX Biosciences (NYSE:MBX) Sets New 52-Week LowTime to Sell? - MarketBeat
MBX Biosciences to Participate in Upcoming November Investor Conferences - The Manila Times
MBX Biosciences (NYSE:MBX) Shares Down 4.5%Here's What Happened - MarketBeat
MBX Biosciences sets IPO terms with plans to raise up to $136 million - MSN
MBX Biosciences, Inc.'s (NYSE:MBX) Quiet Period To End on October 23rd - MarketBeat
MBX Biosciences, Inc.’s Quiet Period Set To Expire on October 23rd (NYSE:MBX) - Defense World
MBX Biosciences (NYSE:MBX) Stock Price Down 4%Here's Why - MarketBeat
MBX Bio drops despite bullish views on Street - MSN
Upstream Bio Leads Life Sciences IPOs With Upsized Listing - BNN Bloomberg
MBX Biosciences (NYSE:MBX) Shares Up 4.6%Here's What Happened - MarketBeat
MBX Biosciences earns Buy rating at three investment firms - MSN
MBX Bio stock drops despite bullish initiations (NASDAQ:MBX) - Seeking Alpha
Guggenheim bullish on MBX Biosciences stock, driven by MBX 2109 potential - Investing.com Canada
MBX Biosciences outlook solid with JPMorgan's overweight rating, eyes key catalysts in next 12 months - Investing.com India
Jefferies sees upside in MBX Biosciences stock, highlights PEP platform advancements - Investing.com India
MBX Biosciences earns Buy rating at three investment firms By Investing.com - Investing.com Canada
Guggenheim Begins Coverage on MBX Biosciences (NYSE:MBX) - Defense World
MBX Biosciences (NYSE:MBX) Now Covered by JPMorgan Chase & Co. - MarketBeat
Jefferies sees upside in MBX Biosciences stock, highlights PEP platform advancements By Investing.com - Investing.com South Africa
MBX Biosciences (NYSE:MBX) Stock Price Down 3.5%Should You Sell? - MarketBeat
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ - GlobeNewswire
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting - Yahoo Finance
MBX Biosciences (NYSE:MBX) Trading Down 4.1% - MarketBeat
Mbx Biosciences Inc Stock (MBX) Financials Data
There is no financial data for Mbx Biosciences Inc (MBX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.89%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):